|
Celgene Expects Sales Boost After FDA Approves Abraxane Combo for NSCLC
The FDA has approved a new indication for Celgene’s Abraxane in combo with carboplatin as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) for patients who can’t undergo surgery or radiation therapy.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives